RedHill Biopharma Awarded $733K U.S. HHS BARDA Contract To Investigate Opaganib As Host-Directed Therapeutic For Ebola Virus Disease
RedHill Biopharma Awarded $733K U.S. HHS BARDA Contract To Investigate Opaganib As Host-Directed Therapeutic For Ebola Virus Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.